{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:44:04Z","timestamp":1793648644619,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001341","name":"Richard and Susan Smith Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzanne Pride Bryan Fund for Breast Cancer Research"},{"name":"Jan Weimer Junior Faculty Chair in Breast Oncology"},{"name":"Regents of the University of California\u2019s California Breast Cancer Research Program","award":["16OB-0149"],"award-info":[{"award-number":["16OB-0149"]}]},{"name":"Regents of the University of California\u2019s California Breast Cancer Research Program","award":["19IB-0124"],"award-info":[{"award-number":["19IB-0124"]}]},{"name":"BRCA Foundation and the Biostatistics Shared Resource (BSR) of the NIH-funded Stanford Cancer Institute","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10549-022-06716-y","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T12:02:21Z","timestamp":1661688141000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer"],"prefix":"10.1007","volume":"196","author":[{"given":"Tanya","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Purington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-9470","authenticated-orcid":false,"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"issue":"5","key":"6716_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol 25(5):486\u2013492","journal-title":"J Clin Oncol"},{"issue":"17","key":"6716_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103(17):1299\u20131309","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6716_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z et al (2005) Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 165(5):552\u2013558","journal-title":"Arch Intern Med"},{"issue":"1","key":"6716_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45\u201353","journal-title":"Lancet Oncol"},{"issue":"12","key":"6716_CR5","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","volume":"37","author":"MS Elisaf","year":"2001","unstructured":"Elisaf MS et al (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37(12):1510\u20131513","journal-title":"Eur J Cancer"},{"issue":"2","key":"6716_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jnci\/djaa096","volume":"113","author":"C Ramin","year":"2021","unstructured":"Ramin C et al (2021) All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J Natl Cancer Inst 113(2):137\u2013145","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6716_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jnci\/djaa097","volume":"113","author":"AH Blaes","year":"2021","unstructured":"Blaes AH, Konety SH (2021) Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship. J Natl Cancer Inst 113(2):105\u2013106","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6716_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J et al (2017) Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer 17(1):11\u201317","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"6716_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15256\/joc.2018.8.125","volume":"8","author":"HS Ng","year":"2018","unstructured":"Ng HS et al (2018) Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study. J Comorb 8(1):16\u201324","journal-title":"J Comorb"},{"issue":"2","key":"6716_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.breast.2013.01.014","volume":"22","author":"A Aydiner","year":"2013","unstructured":"Aydiner A (2013) Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast 22(2):121\u2013129","journal-title":"Breast"},{"key":"6716_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3845","volume":"363","author":"A Matthews","year":"2018","unstructured":"Matthews A et al (2018) Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ 363:k3845","journal-title":"BMJ"},{"issue":"2","key":"6716_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cncr.23171","volume":"112","author":"F Cuppone","year":"2008","unstructured":"Cuppone F et al (2008) Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112(2):260\u2013267","journal-title":"Cancer"},{"issue":"9762","key":"6716_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ van de Velde","year":"2011","unstructured":"van de Velde CJ et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321\u2013331","journal-title":"Lancet"},{"issue":"7011","key":"6716_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/bmj.311.7011.977","volume":"311","author":"CC McDonald","year":"1995","unstructured":"McDonald CC et al (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311(7011):977\u2013980","journal-title":"BMJ"},{"issue":"9","key":"6716_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol 20(9):1489\u20131498","journal-title":"Ann Oncol"},{"issue":"12","key":"6716_CR16","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","volume":"2","author":"R Haque","year":"2016","unstructured":"Haque R et al (2016) Cardiovascular disease after aromatase inhibitor use. JAMA Oncol 2(12):1590\u20131597","journal-title":"JAMA Oncol"},{"issue":"20","key":"6716_CR17","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1200\/JCO.2017.76.3524","volume":"36","author":"R Hamood","year":"2018","unstructured":"Hamood R et al (2018) Diabetes after hormone therapy in breast cancer survivors: a case-cohort study. J Clin Oncol 36(20):2061\u20132069","journal-title":"J Clin Oncol"},{"issue":"10","key":"6716_CR18","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/cncr.26559","volume":"118","author":"LL Lipscombe","year":"2012","unstructured":"Lipscombe LL et al (2012) Association between tamoxifen treatment and diabetes: a population-based study. Cancer 118(10):2615\u20132622","journal-title":"Cancer"},{"issue":"1","key":"6716_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.28395","volume":"120","author":"AW Kurian","year":"2014","unstructured":"Kurian AW et al (2014) Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. Cancer 120(1):103\u2013111","journal-title":"Cancer"},{"key":"6716_CR20","first-page":"970","volume":"2012","author":"SC Weber","year":"2012","unstructured":"Weber SC et al (2012) Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. AMIA Annu Symp Proc 2012:970\u2013978","journal-title":"AMIA Annu Symp Proc"},{"issue":"21","key":"6716_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/eurheartj\/eht462","volume":"35","author":"DL Hare","year":"2014","unstructured":"Hare DL et al (2014) Depression and cardiovascular disease: a clinical review. Eur Heart J 35(21):1365\u20131372","journal-title":"Eur Heart J"},{"issue":"2","key":"6716_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pds.1164","volume":"15","author":"HA Guess","year":"2006","unstructured":"Guess HA (2006) Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf 15(2):81\u201392","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6716_CR23","unstructured":"Therneau T, Crowson C, Atkinson E (2020) Multi-state models and competing risks. [cited 2020]."},{"key":"6716_CR24","unstructured":"Team RC (2020) R: A language and environment for statistical computing. R Foundation for Statistical Computing. Available from: https:\/\/www.R-project.org\/."},{"key":"6716_CR25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B (Method) 57:289\u2013300","journal-title":"J R Stat Soc: Ser B (Method)"},{"issue":"7","key":"6716_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1212\/01.WNL.0000140491.54664.50","volume":"63","author":"CD Bushnell","year":"2004","unstructured":"Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63(7):1230\u20131233","journal-title":"Neurology"},{"issue":"11","key":"6716_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","volume":"18","author":"RS Braithwaite","year":"2003","unstructured":"Braithwaite RS et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18(11):937\u2013947","journal-title":"J Gen Intern Med"},{"issue":"20","key":"6716_CR28","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/jnci\/djh285","volume":"96","author":"AM Geiger","year":"2004","unstructured":"Geiger AM et al (2004) Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 96(20):1528\u20131536","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6716_CR29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1200\/JCO.2008.21.3553","volume":"28","author":"CM Schilder","year":"2010","unstructured":"Schilder CM et al (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294\u20131300","journal-title":"J Clin Oncol"},{"issue":"4","key":"6716_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s11764-019-00782-w","volume":"13","author":"SE Bromley","year":"2019","unstructured":"Bromley SE et al (2019) Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. J Cancer Surviv 13(4):632\u2013640","journal-title":"J Cancer Surviv"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06716-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T18:34:23Z","timestamp":1727894063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06716-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6716"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06716-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Stanford University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A waiver of authorization was granted by the Instituional Review Board of Stanford University for use of deidentified data-posing minimal risk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No individual person\u2019s identifiable data or details are included in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}